AAREY DRUGS & PHARMACEUTICALS
|
|
BOM : 524412     NSE : AAREYDRUGS     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : NA |
Dec 13,2024 |
Price(EOD): ₹ 59.78
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 169.78 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AAREY DRUGS & PHARMACEUTICALS | -4.2% | -2.9% | 40.7% |
SUN PHARMACEUTICAL INDUSTRIES | 0.4% | 0.8% | 45.4% |
CIPLA | -1.5% | -5.1% | 20.3% |
DR REDDYS LABORATORIES | -0.7% | -1.3% | 13.8% |
ZYDUS LIFESCIENCES | -0.5% | 3% | 54.1% |
DIVIS LABORATORIES | -1.4% | 1.2% | 62% |
MANKIND PHARMA | 0% | 0.5% | 38.1% |
TORRENT PHARMACEUTICALS | 0.4% | 6.3% | 60.1% |
LUPIN | -1.5% | -0.6% | 72.3% |
FUNDAMENTAL ANALYSIS OF AAREY DRUGS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AAREY DRUGS & PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
24.59
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 6.89 Cr
[Latest Qtr - Sep2024 - Standalone Results ] 1.3
P/B Calculated based on Book Value of Rs 130.31 Cr
[Latest Year - Mar2024 - Standalone Results ] 0.33
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2024 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
593% 157% 96% |
SHARE PRICE MOMENTUM OF AAREY DRUGS & PHARMACEUTICALS
AAREY DRUGS & PHARMACEUTICALS vs SENSEX
DEBT OF AAREY DRUGS & PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.24 0.33 0.13 0.23 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AAREY DRUGS & PHARMACEUTICALS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AAREY DRUGS & PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-17.15% 216.21% 31.28% 28.92% |
81.81% 101.68% 73.56% 103.57% |
QtrlyTrend |
6 | |
Latest Qtr: Sep2024 | ||
Quarterly Result Analysis → |
AAREY DRUGS & PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about AAREY DRUGS & PHARMACEUTICALS
Is AAREY DRUGS & PHARMACEUTICALS good for long term investment?
As on Dec 13,2024, the Fundamentals of AAREY DRUGS & PHARMACEUTICALS look Poor and hence it may not be good for long term investment ! See Financial Performance of AAREY DRUGS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AAREY DRUGS & PHARMACEUTICALS UnderValued or OverValued?
As on Dec 13,2024, AAREY DRUGS & PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS ?
As on Dec 13,2024, the Intrinsic Value of AAREY DRUGS & PHARMACEUTICALS is Rs. 23.28 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 8.63
Fair Value [Median EV / Sales Model] : Rs. 23.28
Fair Value [Median Price / Sales Model] : Rs. 30.48
Estimated Median Fair Value of AAREY DRUGS & PHARMACEUTICALS : Rs. 23.28
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.